Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 1269

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 8
Chunk 1269
---
; and (ii) in lieu of common stock, pre-funded warrants to purchase 706,250 shares
of common stock and accompanying Class A warrants to purchase up to 706,250
shares of common stock and Class B warrants to purchase up to 706,250
shares of common stock, at a combined public offering price of $0.4.63 per pre-funded warrant and accompanying warrants, which is
equal to the public offering price per share of common stock, and accompanying warrants less the $0.001 per share exercise price of
each such pre-funded warrant.

All pre-funded
warrants issued in the offering were exercised in the quarter ended June 30, 2024. The Class A
and Class B warrants each have an exercise price of $4.64 per
share, are immediately exercisable, and, in the case of Class A warrants, will expire on May
17, 2029, and in the case of Class B warrants, will expire
on May
19, 2025. The exercise price of the Class A and Class B warrants
is also subject to adjustment for stock splits, reverse splits, and similar capital transactions as described in such
warrants.

Maxim Group LLC (“Maxim”),
served as the exclusive placement agent in connection with the offering. We paid Maxim a cash fee of 6.5% of the aggregate gross proceeds
raised at the closing of the offering, and reimbursement of certain expenses and legal fees in the amount of $100,000. We also issued
to designees of Maxim warrants to purchase up to an aggregate of 40,500 shares of common stock (the “Placement Agent Warrants”).
The Placement Agent Warrants have an exercise price of $4.64 per share and have substantially the same terms as the Class A warrants,
except the Placement Agent Warrants are not subject to an exercise price reset, are non-exercisable until November 15, 2024, and will
expire on May 15, 2029.

The gross proceeds from
the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $4.7 million. Net
proceeds, of the offering, after deducting the placement agent fees and expenses and other offering expenses payable by us, were are approximately
$3.5 million. In June 2024, and holders of Class A and Class B warrants exercised 37,500